To sell on a :
1. Market cap less than the funding they have
2. On a revolutionary drug
3. CEO and directors increasing their holdings at 7.5 cents
4. Significant news flow in the quarter ahead
5. Peers in the same space trading 70-100 million market caps on pre clinical success
6. Heavily de risked and very high probability that it will JV and receive non dilutive funding of an additional 5-10 million
To sell on the first point alone is just plain stupidity but it’s the market and you have to love it
Ann: Significant Neuroprotection in NYR Preclinical Brain Injury, page-188
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
-0.005(3.85%) |
Mkt cap ! $22.77M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 12.0¢ | $38.77K | 309.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 191655 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 14843 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| NYR (ASX) Chart |